Skip to main content
. 2009 Nov 4;298(2):F293–F300. doi: 10.1152/ajprenal.00410.2009

Fig. 4.

Fig. 4.

Suppression of cisplatin-induced p53 activation by SAHA. A, B, C: RPTCs were subjected to 6 h of pretreatment without or with 5 μM SAHA. The cells were then incubated for 4 or 18 h with 20 μM cisplatin or 20 μM cisplatin plus 1 μM SAHA. Cell lysate was collected for immunoblot analysis of phospho-p53(serine-15), p53, acetyl-p53(lysine-379), PUMA-α, p21, and β-actin. D, E, F: RPTCs were subjected to overnight pretreatment with or without 1 μM SAHA or 0.1 μM TSA. The cells were then incubated for 4 or 24 h with 20 μM cisplatin or 20 μM cisplatin plus 1 μM SAHA or 0.1 μM TSA. Cell lysate was collected for immunoblot analysis of phospho-p53(serine-15), acetyl-p53(lysine-379), and β-actin.

HHS Vulnerability Disclosure